BR112014028576B1 - cloreto de n-metil-4-benzilcarbamidopiridínio, processo para preparo do mesmo e composição farmacêutica compreendendo o mesmo - Google Patents
cloreto de n-metil-4-benzilcarbamidopiridínio, processo para preparo do mesmo e composição farmacêutica compreendendo o mesmo Download PDFInfo
- Publication number
- BR112014028576B1 BR112014028576B1 BR112014028576-4A BR112014028576A BR112014028576B1 BR 112014028576 B1 BR112014028576 B1 BR 112014028576B1 BR 112014028576 A BR112014028576 A BR 112014028576A BR 112014028576 B1 BR112014028576 B1 BR 112014028576B1
- Authority
- BR
- Brazil
- Prior art keywords
- fact
- methyl
- benzylamide
- chloromethane
- isonicotinic acid
- Prior art date
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 title claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- 238000000034 method Methods 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 230000003612 virological effect Effects 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 60
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 claims description 60
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 39
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 claims description 36
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 16
- YIGMDKYIWMVZDV-UHFFFAOYSA-N n-benzylpyridine-4-carboxamide Chemical compound C=1C=NC=CC=1C(=O)NCC1=CC=CC=C1 YIGMDKYIWMVZDV-UHFFFAOYSA-N 0.000 claims description 15
- 239000012535 impurity Substances 0.000 claims description 13
- 238000002844 melting Methods 0.000 claims description 13
- 230000008018 melting Effects 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 12
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 claims description 11
- 239000011541 reaction mixture Substances 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 5
- 206010022000 influenza Diseases 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 4
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000005956 quaternization reaction Methods 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims description 2
- 239000012043 crude product Substances 0.000 claims 1
- QPWTXLUZSQPLFE-UHFFFAOYSA-N phenylmethanamine;pyridine Chemical group C1=CC=NC=C1.NCC1=CC=CC=C1 QPWTXLUZSQPLFE-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 239000013049 sediment Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 239000011521 glass Substances 0.000 description 16
- 238000001914 filtration Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- ILSOAHPXYZRFBA-UHFFFAOYSA-N n-benzyl-1-methylpyridin-1-ium-4-carboxamide;iodide Chemical class [I-].C1=C[N+](C)=CC=C1C(=O)NCC1=CC=CC=C1 ILSOAHPXYZRFBA-UHFFFAOYSA-N 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 229940126601 medicinal product Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical class NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2012/059258 | 2012-05-18 | ||
| PCT/EP2012/059258 WO2013170901A1 (en) | 2012-05-18 | 2012-05-18 | N-methyl-4-benzylcarbamidopyridinium chloride and a process for its preparation |
| PCT/EP2013/060158 WO2013171307A1 (en) | 2012-05-18 | 2013-05-16 | N-methyl-4-benzylcarbamidopyridinium chloride and a process for its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014028576A2 BR112014028576A2 (pt) | 2017-06-27 |
| BR112014028576B1 true BR112014028576B1 (pt) | 2020-11-03 |
Family
ID=48483057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014028576-4A BR112014028576B1 (pt) | 2012-05-18 | 2013-05-16 | cloreto de n-metil-4-benzilcarbamidopiridínio, processo para preparo do mesmo e composição farmacêutica compreendendo o mesmo |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9493416B2 (enExample) |
| EP (1) | EP2850063B1 (enExample) |
| JP (1) | JP2015517513A (enExample) |
| KR (1) | KR101777561B1 (enExample) |
| BR (1) | BR112014028576B1 (enExample) |
| CA (1) | CA2873977C (enExample) |
| EA (1) | EA025409B1 (enExample) |
| ES (1) | ES2573286T3 (enExample) |
| IN (1) | IN2014DN10683A (enExample) |
| PL (1) | PL2850063T3 (enExample) |
| UA (1) | UA110889C2 (enExample) |
| WO (2) | WO2013170901A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2689775C1 (ru) * | 2018-11-02 | 2019-05-29 | Открытое акционерное общество "Авексима" | Способ промышленного производства N-метил-4-бензилкарбамидопиридиния йодида |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU58612A1 (ru) | 1939-10-29 | 1939-11-30 | П.С. Мордовин | Устройство дл включени в одну станционную линию двухабонентских аппаратов |
| SU548612A1 (ru) | 1975-07-18 | 1977-02-28 | Казанский Химико-Технологический Институт Им.С.М.Кирова | Способ получени 10-хлорфеноксарсина |
| US4115390A (en) * | 1977-08-19 | 1978-09-19 | Nardi John C | Method for the preparation of 1-alkyl pyridinium chlorides |
| ATE178320T1 (de) * | 1992-06-04 | 1999-04-15 | Micro Flo Co | Mepiquat chloride |
| WO2011158058A1 (en) | 2010-06-17 | 2011-12-22 | Farmak International Holding Gmbh | α-CRYSTALLINE FORM OF CARBABENZPYRIDE |
-
2012
- 2012-05-18 WO PCT/EP2012/059258 patent/WO2013170901A1/en not_active Ceased
- 2012-05-18 UA UAA201412193A patent/UA110889C2/uk unknown
-
2013
- 2013-05-16 IN IN10683DEN2014 patent/IN2014DN10683A/en unknown
- 2013-05-16 US US14/368,505 patent/US9493416B2/en active Active
- 2013-05-16 ES ES13724564.3T patent/ES2573286T3/es active Active
- 2013-05-16 JP JP2015512063A patent/JP2015517513A/ja active Pending
- 2013-05-16 BR BR112014028576-4A patent/BR112014028576B1/pt not_active IP Right Cessation
- 2013-05-16 KR KR1020147028207A patent/KR101777561B1/ko not_active Expired - Fee Related
- 2013-05-16 CA CA2873977A patent/CA2873977C/en not_active Expired - Fee Related
- 2013-05-16 EP EP13724564.3A patent/EP2850063B1/en active Active
- 2013-05-16 WO PCT/EP2013/060158 patent/WO2013171307A1/en not_active Ceased
- 2013-05-16 EA EA201492161A patent/EA025409B1/ru not_active IP Right Cessation
- 2013-05-16 PL PL13724564.3T patent/PL2850063T3/pl unknown
-
2016
- 2016-10-20 US US15/298,400 patent/US20170037011A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014028576A2 (pt) | 2017-06-27 |
| JP2015517513A (ja) | 2015-06-22 |
| US20170037011A1 (en) | 2017-02-09 |
| CN104321312A (zh) | 2015-01-28 |
| CA2873977A1 (en) | 2013-11-21 |
| KR20150013124A (ko) | 2015-02-04 |
| EP2850063A1 (en) | 2015-03-25 |
| UA110889C2 (uk) | 2016-02-25 |
| EP2850063B1 (en) | 2016-04-13 |
| PL2850063T3 (pl) | 2016-10-31 |
| US9493416B2 (en) | 2016-11-15 |
| US20140357677A1 (en) | 2014-12-04 |
| CA2873977C (en) | 2019-09-17 |
| KR101777561B1 (ko) | 2017-09-12 |
| WO2013170901A1 (en) | 2013-11-21 |
| EA201492161A1 (ru) | 2015-03-31 |
| ES2573286T3 (es) | 2016-06-07 |
| WO2013171307A1 (en) | 2013-11-21 |
| IN2014DN10683A (enExample) | 2015-08-28 |
| EA025409B1 (ru) | 2016-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2680146T3 (es) | Hidrocloruro de rilpivirina | |
| CN104961731A (zh) | 一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法 | |
| BR112015031619B1 (pt) | Formas cristalinas i e iii de cloridrato de 5-cloro-6-(2-iminopirrolidin-1-il)metil-2,4(1h,3h)-pirimidinodiona, composição farmacêutica e método de produção | |
| TW201938558A (zh) | 吡啶并咪唑類化合物的晶型、鹽型及其製備方法 | |
| JP7303821B2 (ja) | ピリミジニルアミノ－ピラゾール化合物の多形体及び固体形態、ならびに製造方法 | |
| CN102875634B (zh) | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型 | |
| BR112017000605B1 (pt) | Forma policristalina do pró-fármaco de tenofovir, seu método de preparação e seu uso, e composição farmacêutica | |
| RU2485121C1 (ru) | Новые кристаллические формы адефовира дипивоксила и способы его получения | |
| BR112014028576B1 (pt) | cloreto de n-metil-4-benzilcarbamidopiridínio, processo para preparo do mesmo e composição farmacêutica compreendendo o mesmo | |
| CN105879049A (zh) | 一种瑞戈非尼与β-环糊精的包合物及其制备方法 | |
| CN112125868B (zh) | 一种氢溴酸伏硫西汀晶型及其制备方法、组合物与用途 | |
| US11643415B1 (en) | Rabeximod compounds | |
| EP2851363B1 (en) | Agomelatine acid radical composite, and preparation method and application thereof | |
| WO2021073592A1 (zh) | 作为rho激酶抑制剂的苯并吡唑类化合物的盐型、晶型及其制备方法 | |
| CN113896649B (zh) | 一种丙胺卡因晶型及制备方法 | |
| CN114105888B (zh) | 丙基硫氧嘧啶与具有抗氧化活性的营养素小分子的共晶及其制备方法 | |
| BR122014004636B1 (pt) | Forma cristalina i de [cloridrato de 4-metilbenzoato de 4-[2-dimetilamino-1-(1-hidroxiciclohexil)etil]fenila], seu uso e seus métodos de preparação, bem como composição farmacêutica | |
| EP2924024A2 (en) | Solid forms of lorcaserin hydrochloride | |
| PT109445B (pt) | Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose | |
| US11014885B2 (en) | Method for preparing donepezil pamoate | |
| CN104961688A (zh) | 一种表皮生长因子受体激酶抑制剂的磷酸盐及其制备方法 | |
| CN117794913A (zh) | 嘧啶衍生物及其药学上可接受的盐的多晶型物和应用 | |
| BR112022008769B1 (pt) | Processo para a preparação de um citrato férrico (iii) de alta pureza | |
| BRPI0903664B1 (pt) | método de obtenção de nova forma cristalina de lamivudina, seu sal cloridrato monoidratado, formulações farmacêuticas e seus usos | |
| BR112020001123B1 (pt) | Formas cristalinas inovadoras de trifenatato de vilanterol e processos para sua preparação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/05/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2671 DE 15-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |